more

DaVita (DVA)

(Delayed Data from NYSE)

$162.26 USD

-1.85 (-1.13%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $162.26 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

Top 17% (42 out of 252)

Industry: Medical - Outpatient and Home Healthcare

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research Published on October 14,2020

Nevro (NVRO) continues to gain traction from its flagship platform, Senza, and R&D capabilities. However, stiff competition remains a woe.

medical

Here's Why You Should Add AngioDynamics to Your Portfolio Now

by Zacks Equity Research Published on October 13,2020

Investor confidence is high in AngioDynamics (ANGO) stock, thanks to solid prospects.

medical

Will Walgreens (WBA) Post Dull Retail Numbers in Q4 Earnings?

by Zacks Equity Research Published on October 12,2020

Walgreens' (WBA) retail pharmacy international sales remain dull in Q4 on difficult market scenario in the U.K.

Veeva Develops 2 Applications on Veeva Clinical Network (Revised)

by Zacks Equity Research Published on October 12,2020

This should boost Veeva's (VEEV) portfolio of cloud-based offerings for the life sciences industry.

medical

Should Value Investors Buy DaVita HealthCare (DVA) Stock?

by Zacks Equity Research Published on October 09,2020

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

DVANegative Net Change

Pacific Biosciences Unveils Sequel IIe for HiFi Sequencing

by Zacks Equity Research Published on October 08,2020

Pacific Biosciences' (PACB) recently-launched Sequel IIe System is powered by its SMRT technology.

Ecolab Disinfectant Gets EPA Nod for Use Against SARS-CoV-2

by Zacks Equity Research Published on October 07,2020

Ecolab's (ECL) Peroxide Multi Surface Cleaner and Disinfectant is the first EPA-registered disinfectant proven to be effective at killing the SARS-CoV-2 virus.